Cancer Management and Research
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Bortezomib in the management of multiple myeloma
(6923) Total Article Views
Authors: Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al
Published Date September 2009
Volume 2009:1 Pages 107 - 117
Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson, Paul G Richardson
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, and anemia. On a cellular level, the disease is characterized by complex interactions between tumor cells and the surrounding bone marrow microenvironment. Understanding of the relationship between malignant plasma cells and the microenvironment has sparked ongoing efforts to develop targeted therapeutic agents for treatment of this disease. The successful development of the first-in-class small-molecule proteasome inhibitor bortezomib occurred as a result of these efforts. This review focuses on the rationale for bortezomib therapy in the treatment of patients with newly diagnosed and relapsed MM, important treatment-related side effects, and future directions for use of bortezomib and other, emerging proteasome inhibitors.
Keywords: multiple myeloma, bortezomib, stem cell transplantation, peripheral neuropathy
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Paul Richardson
Readers of this article also read:
- ASCO 2013 Meet the Editor
We invite you to meet Prof Dr Hans-Joachim Schmoll at the Dove Medical Press booth 22102 on June 1st at 11am. Prof Dr Schmoll is the Editor-in-Chief of the journal OncoTargets and Therapy (IF 1.26).
- Epigenomics in cancer management
- The bradykinin B2 receptor induces multiple cellular responses leading to the proliferation of human renal carcinoma cell lines
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
- Integrative systems of genomic risk markers for cancer and other diseases: future of predictive medicine